Sedana Medical AB has published a groundbreaking pediatric study in The Lancet Respiratory Medicine, demonstrating the effectiveness and safety of its inhalation sedation device for children aged 3-17 years.

Sedana Medical AB reported an 18% increase in sales for Q1 2025, driven by strong growth in Spain and other key markets, with revenue expected to reach 203.6 million SEK by the end of the fiscal year.

Sedana Medical AB has reported an 18% increase in sales for the first quarter of 2025, driven by strong growth in Spain, and has seen a decrease in operating loss, indicating a move towards financial stability.

Sedana Medical AB has achieved an 18% increase in sales for Q1 2025, driven by growth in markets outside Germany, but faces significant financial challenges, including a reduced operating loss but a negative Price Earnings Ratio.

Sedana Medical AB reports an 18% increase in sales for Q1 2025, driven by strong growth in Spain and stabilization in Germany, with the company positioning itself for continued success in the healthcare equipment and supplies industry.